Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (CATX): 9 pipeline candidates · ~25 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
24.9 months
D/E 0.18 · 0% dilution
Lead: Phase 1/Phase 2
9 candidates
N/A
N/A
A transparent, data-derived signal for Perspective Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$336.4M
Cash
$54.0M
Quarterly Burn
$31.5M
Runway
24.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| [203pb]pb-psv359 | Phase 1/Phase 2 |
| [203pb]vmt-α-net | Phase 1/Phase 2 |
| [203pb]vmt01 | Phase 1/Phase 2 |
| [212pb]pb-psv359 | Phase 1/Phase 2 |
| [212pb]vmt-α-net | Phase 1/Phase 2 |
| [212pb]vmt01 | Phase 1/Phase 2 |
| PSV359 | Phase 1/Phase 2 |
| VMT-α-NET | Phase 1/Phase 2 |
| VMT01 | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
135
Total value held
$317.4M
| Holder | Shares | Value |
|---|---|---|
| avidity partners management lp | 12,099,998 | $48.8M |
| vanguard capital management llc | 8,757,912 | $36.5M |
| commodore capital lp | 6,336,782 | $26.4M |
| blackrock, inc. | 5,348,561 | $22.3M |
| millennium management llc | 4,046,640 | $16.9M |
| citadel advisors llc | 3,640,204 | $15.2M |
| affinity asset advisors, llc | 3,164,582 | $13.2M |
| state street corp | 3,132,670 | $13.1M |
| balyasny asset management l.p. | 2,994,460 | $12.5M |
| morgan stanley | 2,983,342 | $12.4M |
Showing top 10 of 135 institutional holders of Perspective Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Perspective Therapeutics, Inc.'s pipeline?
Perspective Therapeutics, Inc. (CATX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Perspective Therapeutics, Inc.'s lead drug candidate?
Perspective Therapeutics, Inc.'s most advanced tracked candidate is [203pb]pb-psv359 (Phase 1/Phase 2) for Pancreatic Ductal Adenocarcinoma.
What is Perspective Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Perspective Therapeutics, Inc. has approximately 24.9 months of cash runway.
What is Perspective Therapeutics, Inc.'s market capitalization?
Perspective Therapeutics, Inc.'s market capitalization is approximately $336.4M.
Who is the CEO of Perspective Therapeutics, Inc.?
Mr. Johan M. Spoor is the chief executive officer of Perspective Therapeutics, Inc. (CATX).
Get the full picture on Perspective Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.